In a major policy shift, the U.S. Food and Drug Administration is reconsidering restrictions on several controversial peptides, including trending compounds like BPC 157 and Melanotan II. The move comes as demand for FDA's Overreach on Compounded Peptides The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York RFK Jr. & claimed regenerative peptides like BPC 157 The Niche BPC 157 + TB 500 blend 10mg (RUO) Tide Labs Tide Labs